INTRODUCTION
Researchers have studied numerous underlying risk factors associated with the occurrence of major cardiovascular events, including suboptimal lipid concentrations, obesity, hypertension, the presence of comorbidities, and smoking. [1] [2] [3] [4] It has been well established that dyslipidemia is associated with excess risk of developing cardiovascular disease (CVD). A low concentration of high-density lipoprotein cholesterol (HDL-C), the second most common lipid abnormality in patients with CVD (~35%, incidence among men and ~40% among women), [4] [5] [6] has increasingly been recognized as a strong and independent predictor of cardiovascular risk. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] HDL-C, a complex of Apo-A lipoproteins, has antioxidative, antiproliferative, antithrombotic, and anti-inflammatory properties, 18, 19 and is known to be protective against CVD by mediating the process of reverse cholesterol transport, which involves the transfer of excess cholesterol from macrophages in the peripheral tissues through the blood stream to the liver, where it metabolizes the cholesterol and excretes it into the bile.
19-21
The Framingham Heart Study (FHS) was the first major study to demonstrate the inverse association between HDL-C concentration and cardiovascular risk, in a cohort of 2815 individuals 49 to 82 years of age who were followed up for approximately 4 years. This relationship was present at all concentrations of low-density lipoprotein cholesterol (LDL-C), but the highest risk of coronary heart disease (CHD) was associated with low HDL-C coupled with high LDL-C. 22 The FHS investigators also found that HDL-C was the strongest lipid predictor of coronary artery disease risk in men and women >49 years of age. 
Study Objective
The primary objective of the present study was to determine the association between change in HDL-C concentrations from baseline and risk of a major cardiovascular event in a commercially insured population cohort with suboptimal HDL-C and LDL-C concentrations at baseline.
MATERIALS AND METHODS

Study Design
A retrospective, longitudinal study was conducted using enrollment information and medical and pharmacy claims data from the i3
Ingenix LabRx administrative claims database of a large US health plan. The health plan comprises discounted fee-for-service independent practice association plans throughout the US, with a preponderance of members in the south and midwest. At the time the study was conducted, medical and pharmacy data were available for approximately 14 million health plan enrollees.
The data were de-identified and accessed using techniques that are in compliance with the Health Insurance Portability and Accountability Act. 46 As no identifiable protected health information was extracted during the course of the study, institutional review board approval was not required.
Study Population Identification
Commercial health plan members were Edition codes listed in Table 1 . and other covariates considered predictive of major cardiovascular events (ie, the presence of CVD, diabetes, angina, ischemic heart disease, hypertension, cardiac conduction disorder, congestive heart failure, or cerebrovascular disease at baseline).
RESULTS
Study Population Identification
A total of 1,388,813 individuals were identified who had at least one complete lipid panel result from the period January 1, 2000 to 38.12, 38.13, 38.18, 39.25, 39.26, 39.29, 39.50, 39.90, 88.48, 88.77 CPT-4 procedure codes: 33510 -33545, 33572, 34101, 34111, 34201, 34203, 35301, 35311-35381, 35390, 35454, 35456, 35459, 35470, 35473, 35474, 35482, 35483, 35485, 35492, 35493, 35495, 35533, 35541, 35546, 35641, 35646, 35548, 35549, 35551-35571, 35654, 36230, 36240 -36248, 75500, 75501, 75505 -75507, 75509 -75511, 75523, 75524, 75527, 75528, 75552-75556, 75710, 75716, 76499, 78460 -78483, 92975, 92977, 92980 -92984, 92995, 92996, 93501-93536, 93542, 93543, 93539, 93540, 93545, 93547-93553, 93555, 93923, 93992 CABG=coronary artery bypass graft; CPT=Current Procedural Terminology; CVD=cardiovascular disease; ICD=International Classification of Diseases. 
Descriptive Statistics
The mean and median durations of follow-up were 1120 and 979 days, respectively (range, 18
to 2892 days). The mean time between baseline lipid profile assessment and the subsequent lipid measurement was 973.4 days (SD 601.7).
Patients ranged from 50 to 84 years of age, and the mean age at index date was 59.3 years (Table 2 ). The majority (56.33%) of patients were female (Table 3) . Mean baseline HDL-C was 1.02 mmol/L (39.4 mg/dL) ( Table 2 ). The lowest HDL-C concentration was 0.59 mmol/L (23 mg/ dL), and the highest was 1.27 mmol/L (49 mg/ dL) (data not shown).
Hypertension was the most common comorbidity assessed at baseline, with a prevalence of 53.19%, and diabetes was the second most common, present in 22.75% of patients. Angina was the only other comorbidity that was present in more than 10% of the study patients (Table 3) . 
Risk Estimates
Parameter estimates and hazard ratios for all values are shown in Table 4 , with upper and lower confidence limits provided for all variables.
Demographic Variables
A 1-year increase in age above 50 (at index date) was associated with a 3.9% increase in the probability of occurrence of a major cardiovascular event, after adjustment for other variables associated with cardiovascular risk ( 
Laboratory Values
There was a statistically significant association between change from baseline HDL-C and risk Table 4 11, 12, 15, 17, 18, 20, 23, 25, 26 The only other retrospective claims-based analysis we identified that evaluated the association between HDL-C and cardiovascular risk (Nichols et al. 47 ) reported findings consistent with ours, and, similar to our patient cohort, their study population also had low HDL-C concentrations at baseline. Nichols et al. by Koro et al. 14 They studied a cohort of 6928 patients in an urban primary care practice who had two or more lipid measurements obtained 
Study Limitations
Interpretation of the study findings must take into consideration certain limitations that are inherent to the use of claims data. Presence of a diagnosis code on a medical claim is not positive presence of disease, as the diagnosis code may be incorrectly coded or included as a rule-out criterion rather than actual disease.
In addition, claims data do not reveal patient lifestyle information that could have an effect on study outcomes, such as smoking, obesity, exercise, and diet. As patients served as their own controls in this study, only large and sustained changes in these behaviors over time would impart significant bias. Research suggests that most patients are unable to sustain these types of changes over a long period of time. 50, 51 Finally, results from this retrospective claims analysis may be less generalizable to populations that include persons without public health insurance. 
CONCLUSION
